Investors with an interest in Medical - Drugs stocks have likely encountered both Jazz Pharmaceuticals (JAZZ) and Catalent (CTLT). But which of these two companies is the best option for those looking for undervalued stocks?

Investors interested in Medical - Drugs stocks are likely familiar with United Therapeutics (UTHR) and Catalent (CTLT). But which of these two companies is the best option for those looking for undervalued stocks?

Catalent's (CTLT) latest capability expansion is expected to boost its business in the global clinical trials space in its Clinical Development & Supply network.

Investors with an interest in Medical - Drugs stocks have likely encountered both United Therapeutics (UTHR) and Catalent (CTLT). But which of these two stocks offers value investors a better bang for their buck right now?

SOMERSET, N.J.--(BUSINESS WIRE)--Catalent, Inc. (NYSE: CTLT), the leader in enabling the development and supply of better treatments for patients worldwide, today announced it has completed expansion of its clinical supply facility in Schorndorf, Germany. The Schorndorf site, Catalent's flagship European facility, provides comprehensive clinical supply services, including packaging, storage and distribution. The expansion increases the site's footprint by 32,000 square feet (3,000 square meters.

Investors with an interest in Medical - Drugs stocks have likely encountered both United Therapeutics (UTHR) and Catalent (CTLT). But which of these two companies is the best option for those looking for undervalued stocks?

Shares of Catalent Inc CTLT, which manufactures Elevidys, are trading higher with a strong session volume of 3.6 million compared to an average volume of 1.6 million.

Catalent (CTLT) reported earnings 30 days ago. What's next for the stock?

Catalent said on Wednesday its stockholders have voted to approve its deal with Novo Holdings, the parent company of Novo Nordisk.

SOMERSET, N.J.--(BUSINESS WIRE)--Catalent, Inc. (“Catalent,” NYSE: CTLT), a leader in enabling the development and supply of better treatments for patients worldwide, today announced that, at its Special Meeting of Stockholders (the “Special Meeting”) held earlier today, its stockholders voted to approve the pending transaction under which Novo Holdings A/S (“Novo Holdings”) will acquire all outstanding shares of Catalent for $63.50 per share in cash (the “Merger”). “Today's outcome represents.

AUSTIN, Texas--(BUSINESS WIRE)--Surely Wines, a trailblazer in the premium non-alcoholic wine space, is pleased to announce the appointment of Brandon Joldersma as the company's new Chief Executive Officer, effective February 2024. Joldersma's appointment coincides with a new fundraising round led by Pure Ventures, with additional investors joining Surely's mission to elevate the alcohol-free and low-alcohol beverage market while expanding its offerings within this burgeoning industry. “I'm hon.

Catalent's (CTLT) new tie-up to support the development and commercial manufacturing of safe, high-quality AAV gene therapies to provide life-saving treatments to cancer patients.